|Mr. Troy M. Cox M.B.A.||Exec. Chairman||14k||N/A||1964|
|Dr. Roy Smythe M.D.||CEO & Director||1.27M||N/A||1962|
|Mr. Shaun M. Blakeman||Chief Financial Officer||316.49k||N/A||1978|
|Dr. Jason Cleveland Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Dr. Nebojsa Janjic Ph.D.||Chief Science Officer||N/A||N/A||1961|
|Mr. Ruben Gutierrez J.D.||Gen. Counsel||N/A||N/A||1975|
|Ms. Alison Marie Roelke||Sr. VP of People & Culture||N/A||N/A||1974|
|Dr. Stephen A. Williams BS, MB, Ph.D.||Chief Medical Officer||N/A||N/A||1960|
|Mr. Todd Johnson||Exec. VP of Diagnostics Bus. Unit||N/A||N/A||N/A|
|Mr. Adam Taich||Exec. VP of Life Sciences Bus. Unit||N/A||N/A||N/A|
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
SomaLogic, Inc.’s ISS governance QualityScore as of 1 December 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 8; Compensation: 8.